Donate For Public and Patients Store Search

F079 - Psoriasis and Atopic Dermatitis: Advances in Immunology and Therapy

Saturday, March 2; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Evaluate recent updates in immunology of psoriasis and atopic dermatitis.
  • Discuss emerging therapies for psoriasis and atopic dermatitis.

Description

Psoriasis and atopic dermatitis are common, immune-mediated chronic diseases. We will compare and contrast the immunology of these two conditions. We will discuss emerging therapeutic options of both conditions (topical, oral, phototherapy, biologic, and pipeline).

Disclosures

  • Bhutani, Tina, MD: Eli Lilly and Company – I(Grants/Research Funding); Janssen Research & Development, LLC – I(Grants/Research Funding); Merck & Co., Inc – I(Grants/Research Funding); Regeneron – C(Fees); Strata Skin Sciences – I(Grants/Research Funding);
  • Eichenfield, Lawrence F., MD: Abbvie – I(Grants/Research Funding); Almirall – C(H); Anacor Pharmaceuticals, Inc. – C(H); Asana BioSciences – Data Safety Monitoring Board(H); Cutanea Life Sciences – C(H); Dermavant Sciences, Inc. – C(H); Dermira – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Forte – A(H); Galderma Laboratories, L.P. – C(H), I(Fees); Glenmark Pharmaceuticals, Inc. – Data Safety Monitoring Board(H); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); MatriSys Bioscience – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H); Pfizer Inc. – C(H), I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Fees); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); Verrica Pharmaceuticals Inc – A(SO), C(H), I(Grants/Research Funding); Wiley-Blackwell – O(H);
  • Guttman, Emma, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Almirall – A(H), C(H), I(Grants/Research Funding); Amgen – C(H), I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Asana Biosciences, LLC – A(H), C(H), I(Grants/Research Funding); Boehringer Ingelheim – A(H), C(H), I(Grants/Research Funding); Cara Therapeutics – A(H), C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Concert Pharmaceuticals – C(H), I(Grants/Research Funding); DBV Technologies – A(H), C(H); Dermavant Sciences – A(H), I(Grants/Research Funding); Dermira – A(H), C(H), I(Grants/Research Funding); DS Biopharma – C(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding); EMD Serono – C(H); Escalier – A(H), C(H); FLX Bio – C(H); Galderma Research & Development, LLC – A(H), C(H), I(Grants/Research Funding); Glenmark Generics Inc. – A(H), C(H), I(Grants/Research Funding); Incyte Corporation – A(H); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – A(H), C(H), I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novan – A(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H), I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Sanofi – A(H), C(H); Sienna Biopharmaceuticals – A(H), C(H), I(Grants/Research Funding); UCB – I(Grants/Research Funding); Union Therapeutics – C(H), I(Grants/Research Funding);
  • Wu, Jashin J., MD: C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); BMS – C(H); Celgene – C(H), SP(H); Demira – C(H); Dr Reddy's Laboratory – C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding); Janssen Biotech – C(H); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Leo Pharma Inc – C(H); Novartis – C(H), I(Grants/Research Funding), SP(H); Ortho Dermatologics – C(H); Pfizer Inc. – C(H); Promius Pharma, LLC – C(H); Regeneron – C(H), SP(H); Sanofi Genzyme – SP(H); Sun Pharmaceutical Industries Ltd. – C(H), SP(H); UCB – C(H), SP(H); Valeant Pharmaceuticals North America LLC – C(H), SP(H);
  • Yamauchi, Paul Steven, MD, PhD: AbbVie – C(H), I(Grants/Research Funding), SP(H); Akros Pharma, Inc. – I(Grants/Research Funding); Almirall – SP(H); Amgen – A(H), C(H), I(Grants/Research Funding), SP(H); AnaptysBio – I(Grants/Research Funding); Arcutis, Inc. – I(Grants/Research Funding); Boehringer Ingelheim – I(Grants/Research Funding); Botanix Pharmaceuticals – I(Grants/Research Funding); Bristol-Myers Squibb – I(Grants/Research Funding); Celgene Corporation – C(H), I(Grants/Research Funding), SP(H); Demira – SP(H); Dermavant Sciences – I(Grants/Research Funding); Dermira – A(H), I(Grants/Research Funding), SP(Grants/Research Funding); Escalier – I(Grants/Research Funding); Galapagos NV – I(Grants/Research Funding); Galderma USA – I(Grants/Research Funding); Genentech, Inc. – I(Grants/Research Funding); Glenmark Pharmaceuticals, Inc. – I(Grants/Research Funding); Hovione – I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Janssen-Ortho Inc. – C(H), I(Grants/Research Funding), SP(H); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Leo Pharma Inc – I(Grants/Research Funding), SP(H); LEO Pharma, US – C(H); Lilly ICOS LLC – A(H), I(Grants/Research Funding), SP(H); Medimmune – I(Grants/Research Funding); Menlo Therapeutics – C(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding), SP(H); Ortho Dermatologics – C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – C(H), I(Grants/Research Funding), SP(H); Regeneron – C(H), I(Grants/Research Funding), SP(H); Sandoz, a Novartis company – I(Grants/Research Funding); Sanofi/Regeneron – SP(H); Sol-Gel Technologies – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H), I(Grants/Research Funding), SP(H); UCB – C(H), I(Grants/Research Funding), SP(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding);
Schedule
Saturday, March 2
3:30 PM
Dr. Wu / Welcome and introduction
3:35 PM
Dr. Guttman / Atopic dermatitis: the pathogenesis of the disease and link to therapeutic development
3:55 PM
Dr. Eichenfield / Atopic dermatitis: therapy
4:20 PM
Dr. Yamauchi / Psoriasis: immunology
4:40 PM
Dr. Bhutani / Psoriasis: oral therapy, topical therapy, and phototherapy
5:05 PM
Dr. Wu / Psoriasis: biologics
Event Details
  • Date
    Saturday, March 2
  • Time
    3:30 PM - 5:30 PM
  • Location
    Salon H
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Jashin J. Wu, MD, FAAD
Speakers
  • Emma Guttman, MD, PhD, FAAD - Handout
  • Lawrence F. Eichenfield, MD, FAAD
  • Paul Steven Yamauchi, MD, PhD, FAAD
  • Tina Bhutani, MD, FAAD